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Across multiple sectors, including food, cosmetics and pharmaceutical industries, there is a 
need to predict the potential effects of xenobiotics. These effects are determined by the 
intrinsic ability of the substance, or its derivatives, to interact with the biological system, 
and its concentration-time profile at the target site. Physiologically-based kinetic (PBK) 
models can predict organ-level concentration-time profiles, however, the models are time 
and resource intensive to generate de novo. Read-across is an approach used to reduce or 
replace animal testing, wherein information from a data-rich chemical is used to make 
predictions for a data-poor chemical. The recent increase in published PBK models presents 
the opportunity to use a read-across approach for PBK modelling, i.e. to use PBK model 
information from one chemical to inform the development or evaluation of a PBK model for 
a similar chemical. Essential to this process, is identifying for which chemicals a PBK model 
already exists. Herein, the results of a systematic review of existing PBK models, compliant 
with Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) format, 
are presented. Model information including species, sex, life-stage, route of administration, 
software platform used and availability of model equations was captured for 7,541 PBK 
models. Chemical information (identifiers and physico-chemical properties) has also been 
recorded for 1,150 unique chemicals associated with these models. This PBK model dataset 
has been made readily accessible, as a Microsoft Excel spreadsheet, providing a valuable 
resource, for those developing, using or evaluating PBK models in industry, academia and 








Humans, like other animals, are exposed daily to a multitude of chemicals of anthropogenic 
origin, including pharmaceuticals, food additives, pesticides, consumer goods and cosmetic 
ingredients. The safety assessment of chemicals is a legal requirement and essential to 
ensure safe use for workers and consumers, as well as protection of domestic/farm animals 
and environmental species. However, for the majority of chemicals there is a lack of 
available data for safety assessment, hence predictive models are essential. Predicting 
toxicity requires knowledge of both the intrinsic activity of the chemical (or its derivatives) 
and the extent to which the organism is exposed. Whilst external exposure, or dose, has 
traditionally been used in assessments, it is recognised that the dose at the target site, i.e. 
organ-level exposure, is the more relevant measure, being causally linked to observed 
toxicity.1 Similar reasoning applies in product design where the internal exposure level is 
linked with a desirable (e.g. therapeutic) effect. In terms of legislation, kinetic data is a 
specific requirement for plant protection and biocidal product safety assessment and, whilst 
not formally required, incorporation of such data is widely recommended in other 
regulations, such as for classification, labelling and packaging (CLP) and the Registration, 
Evaluation Authorisation and restriction of Chemicals (REACH).2 Guidance documents from 
the European Chemicals Agency3 and the Scientific Committee on Consumer Safety4 
recommend making use of all available data (including kinetic data) to support decision-
making. Whilst general information regarding absorption, distribution, metabolism or 
excretion (ADME) may be useful, more accurate prediction requires organ-level 
concentration-time profiles. Physiologically-based kinetic (PBK) models (synonymous with 
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physiologically-based pharmacokinetic, toxicokinetic or biokinetic (PBPK, PBTK or PBBK) 
models) are employed in numerous industries to provide such predictions. 
In a PBK model the body is represented as a series of compartments (for example individual 
organs) connected by blood flow. The models use knowledge of physiology and anatomy 
(such as organ volumes and cardiac output), in combination with chemical-specific 
information (such as solubility and partitioning behaviour) to predict the concentration 
time-profile of the chemical in tissues, cellular compartments or sub-compartments. 
Differential equations are used to describe the rate of change of concentration of the 
chemical in each compartment, as summarised in Figure 1. Detailed information on how to 
construct and validate PBK models, their applications in different sectors and tools available 
to support PBK modelling have been well-reported previously.1, 5-9 Of particular note, is the 
recent Organisation for Economic Cooperation and Development (OECD) guidance on the 
characterisation, validation and reporting of models for regulatory purposes.10 This 
document builds on the principles described in the WHO report of 20101 but focuses on the 
use of alternative approaches (in silico and in vitro) for parameterising PBK models. The 
potential for applying new approach methodologies (NAMs) and next generation (NG) 
methods to support the development and use of PBK models in safety assessment, was also 
promulgated by Paini and colleagues.11 PBK models can assimilate new information as it 
becomes available to increase predictive capacity; these models provide an advantage over 




For environmental chemicals, the numerous applications of these models include: 
determining the dose at target tissue following external exposure; route-to-route 
extrapolation; dose extrapolation; inter- and intra-species extrapolation (accounting for 
species, population or genetic variability through adaptation of physiological and anatomical 
parameters); in vitro-to-in-vivo extrapolation (IVIVE); ascertaining safe levels based on tissue 
dosimetry; estimating chemical exposure from biomonitoring or epidemiological data (using 
reverse dosimetry) and assessing potential for bioaccumulation. These applications 
complement the traditional role of PBPK modelling of drugs where they can be utilised to 
predict first dose in man, potential for drug-drug interactions or the influence of health 
status (e.g. hepatic impairment) on kinetics.13  
ECHA reports that read-across is the most commonly used alternative method to reduce or 
replace animal testing in safety assessment.14 In this approach, information from a data-rich 
(source) chemical is used to predict information for a data-poor (target) substance that is 
considered similar.3 Kinetic information plays a key role in supporting read-across 
predictions3,15 and recent efforts have aimed to increase the accessibility of such data. Sayre 
and co-workers16 published a database of time-series concentration data, extracted from an 
extensive search of the literature, and Pawar and co-workers identified 38 databases 
containing a range of ADME-relevant data as part of their overall review of resources to 
support read-across and in silico model development.17 PBK models provide an additional 
opportunity to derive data to support read-across. Data may be acquired either from a PBK 
model for the chemical under investigation (the target chemical) or from a PBK model for an 
existing chemical considered similar to the target (a source chemical). This latter approach, 
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wherein an existing PBK model for a source chemical is used as a template for a target 
chemical, is contingent upon the identification of existing, suitable PBK models. 
Over the past 30 years the number of published PBK models and their applications has 
increased significantly.18 In 2016 Lu and co-workers published a PBK Knowledgebase, 
comprising 307 chemicals for which PBK models were available from papers published 
between 1977 and 2014.19 In their report the authors described two case studies, wherein 
PBK models from the Knowledgebase were used to inform the development of PBK models 
for “similar” chemicals. In their study chemical analogues were identified based on similarity 
of physico-chemical properties, although it is recognised that there is no consensus as to the 
best method to determine similarity.20  Ellison and Wu successfully demonstrated an 
analogous approach wherein a PBK model for a target chemical was evaluated using 
information from source chemicals identified as structural or functional analogues.21 In 
order to assist researchers in identifying existing PBK models, a spreadsheet of those 
collated from the literature by the US Environmental Protection Agency (EPA), was made 
available via Figshare.22 This resource included information on species, gender, life-stage, 
route of administration, compartments and PubMed ID for the source of the models. 
An enriched version of this PBK Knowledgebase was recently used as a proof-of-principle to 
demonstrate that information from an existing PBK model could be used, in a read-across 
approach, to inform safety assessment.23 In the analysis, methyleugenol was considered as a 
target chemical with estragole and safrole being identified as suitable source chemicals 
(with respect to structural similarity). This approach was also successful, exemplifying how 
information from an existing PBK model could assist the development of a model for a 
similar chemical. Making best use of existing data and in particular the application of the 
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read-across approach are recognised as important tools in reducing animal testing.24 In 
order to facilitate the application of this approach, it is essential to identify chemicals for 
which PBK models are available. As “similarity” is often considered in relation to structure or 
physico-chemical properties it is also important to ascertain the nature of the chemicals for 
which models are available, comparing their characteristics to existing chemical datasets. 
Having information regarding the chemicals and the models in a readily accessible and 
updateable resource would be a significant asset for researchers, industry and regulators, 
with the potential to reduce the number of animals used in drug development and chemical 
safety assessment. 
Several key features characterise an individual PBK model, these are represented in Figure 1 
and include species, sex, life-stage, route of administration and the compartments required 
to accurately describe the time-course of the chemical. In some models, key organs (such as 
liver, lung etc) are incorporated individually as compartments, in others these are further 
divided into constituent sub-compartments (for example considering histopathological 
regions or explicitly including lymph or interstitial / vascular space) giving higher-level, more 
complex models. In other scenarios, organs are grouped together (referred to as “lumping”) 
to create simpler models, for example all poorly perfused organs are considered as one 
compartment and all highly-perfused organs are considered as another. In addition to the 
physiological and anatomical information required, chemical-specific data is also a pre-
requisite. A substance may be identified using common names or chemical identifiers such 
as the Chemical Abstracts Registry (CAS) number, a Simplified Molecular Input Line Entry 
System (SMILES) string or the International Chemical Identifier Key (InChiKey). Ideally 
multiple identifiers should be incorporated in the dataset to avoid ambiguity. Model 
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development can be performed using a range of software, the equations employed may be 
specified within the publication itself (or as part of the supplementary information 
accompanying the article). Within this systematic review, key model characteristics, such as 
species, sex, life-stage, route of administration, compartments, availability of model 
equations and chemical identifiers were captured within the PBK model dataset, as 
summarised in Figure 1.  
The second part of the analysis relates to the assessment of the chemical space coverage of 
the PBK model dataset. There is no simple process by which a chemical can be designated as 
being a particular “type” – for example cosmetic ingredients may also be food additives; 
botanicals may have pharmaceutical properties etc. Consequently, in order to assess the 
nature of the chemicals in the PBK model dataset, key physico-chemical properties were 
generated and compared to those of chemicals appearing in other datasets. Datasets 
studied were botanicals, pesticides, pharmaceuticals, food, cosmetic ingredients and REACH 
chemicals. The number of chemicals in the PBK model dataset that also appeared in each of 
the other datasets was ascertained.  
In summary, the aim of this systematic review was the curation of a data resource for 
existing PBK models. Relevant information for the models (species, sex, life-stage, substance 
identity, software used etc) was captured in a flexible spreadsheet format. The chemical 
space occupied by PBK models (in terms of physico-chemical properties) was compared to 
that of other chemical types, using six existing datasets. This resource has been created to 
assist the development and evaluation of PBK models using existing data, thereby reducing 








This systematic review was prospectively registered on PROSPERO, the National Institute for 
Health Research’s international prospective registration system with the review question 
stipulated as: “For which substances are physiologically-based kinetic (PBK) models available 
and which species, genders, life-stages and routes of administration have been investigated 
for these substances? This will include determining the chemical space coverage of the 
models and the availability of the associated model equations within the literature.”25 The 
review complies with the PRISMA reporting standards - the PRISMA checklist is available as 
Supplementary Material (iii). 
Briefly, following a scoping study of potentially useful databases and search terms, Scopus 
(https://www.scopus.com/), PubMed (https://pubmed.ncbi.nlm.nih.gov/) and Web of 
Science (https://www.webofknowledge.com) were selected as the most appropriate 
databases for identifying published papers on PBK models. The search of these databases 
was completed in October 2020. The search terms (“pbpk” OR “pbk” OR “pbbk” OR “pbtk” 
OR “pbpd” OR “pbpm” OR “physiologically based”) AND (“pharmacokinetic” OR 
“toxicokinetic” OR “biokinetic” OR “pharmacodynamics” OR “biopharmaceutical”) were 
used to search abstracts, titles and keywords of papers within each database, across all 
years available. The systematic review management tool Covidence was used for processing 
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papers for the review (https://www.covidence.org/, accessed May 2021). A total of 14,803 
papers were initially identified, however following automated removal of duplicates in 
Covidence, 6,771 remained. All abstracts were screened independently by two researchers 
with all conflicts being resolved by discussion. The inclusion criteria encompassed PBK 
models for all routes of administration for chemical, biological and carrier systems, including 
cases where normal physiology was altered or interactions between administered 
substances were investigated. Models that could not be associated with a specific substance 
(such as generic models applicable to large groups of compounds) were excluded. Where an 
abstract was associated with a paper that had subsequently been retracted it was ensured 
that this model was excluded from the dataset. Although standard practice in other 
systematic reviews, assessment of the quality of the reported models and risk of bias in 
reporting was considered unnecessary for this review. Our intention here was to document 
all available models, enabling interested researchers to rapidly identify potentially useful 
models to assist with future model development. The assessment of PBK model quality 
(aside from fundamental considerations relating to good modelling practice) needs to be 
considered in terms of fitness for a given purpose,10 it is therefore context dependent and 
remains the decision of the model user. Following abstract screening, 3,120 abstracts were 
retained for full text screening. PBK model data were extracted from 1,649 of these papers, 
resulting in 7,541 individual models being captured. Note that if oral and intravenous dosing 
were used for both male and female subjects for the same chemical this would be extracted 
as four individual models, hence there are many more models than individual chemicals. 
Reasons for exclusion of papers during full text screening included: PBK model not being 
reported in the article; the article referenced a previously published model with no 
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adaptations (information on the PBK model was extracted from the original publication); full 
article not being available in English or not being reasonably accessible.  
 
Extraction of data from available PBK models 
Data were manually extracted from these 1,649 papers by one reviewer, with information 
being acquired from text, tables, figures and supplementary information. The data were 
entered into a Microsoft Excel spreadsheet that captured details of the chemical: parent 
and metabolites specified where appropriate, species (with sub-category where relevant), 
sex, life-stage, route of administration, literature reference for the model (with DOI), 
compartments considered in the model, the software employed and the availability of PBK 
model equations within the article. Controlled vocabulary was used where possible to 
ensure consistency of data extraction and to enable the resulting spreadsheet to be readily 
filtered and searched for specific types of models, i.e. controlled vocabulary was used for 
species, sex, life-stage, route of administration, availability of equations and software used. 
The vocabulary was empirically derived, to enable the most efficient searching, the full 
rationale is given in the Supplementary Material (i). For example, life stages can be reported 
in multiple ways – no. of weeks, months, years of age, young adult, adult, neonate, young 
child, juvenile etc. Therefore, for consistency this information was allocated to the more 
generic categories of pre-birth or pre-hatch; from birth or hatch up to adult; adult; 
pregnant; old age (if specified) as well as a generic category for health compromised 
(excluding old age) individuals.  
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Chemical identifier information was obtained by manually inputting the chemical name (as 
given in the publication) into PubChem (https://pubchem.ncbi.nlm.nih.gov/; last accessed 
May 2021) and extracting the molecular weight, canonical SMILES, isomeric SMILES, 
InChiKey and CAS number. The CAS registry number from PubChem was used as input for 
the COSMOS database, version 2 (https://cosmosdb.eu, accessed April 2021). Where 
available, the CAS registry number and chemical name, as recorded in COSMOS, were 
extracted to confirm the identity of the chemical; the COSMOS ID was also extracted. This 
information was captured by one reviewer. An assessment of the reliability of screening and 
data extraction was undertaken and is reported below. 
Assessment of the chemical space coverage of the PBK model dataset in relation to 
other chemical datasets 
In order to identify the nature of the chemicals in the PBK model dataset and to compare 
the chemical space coverage (in terms of key physico-chemical properties) six existing data 
sets were investigated. These have been compiled in-house at Liverpool John Moores 
University and comprise: botanicals; pesticides; cosmetic ingredients (obtained from 
COSMOS db version 2 (https://cosmosdb.eu; accessed April 2021); food additives (obtained 
from http://foodb.ca; accessed April 2021); pharmaceuticals (obtained from 
www.drugbank.ca; accessed April 2021) and REACH chemicals as summarised in Table 1. 
Canonical SMILES for all chemicals in these datasets were generated using OpenBabel 
(v.3.0.0; http://openbabel.org/wiki/Main_Page; accessed April 2021). From the PBK model 
dataset 1,150 unique SMILES were identified with 1,187 unique InChiKeys (note that 
chemical isomers may have the same SMILES string but different InChiKeys). In order to 
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determine how many chemicals with PBK models were present in each of the other six 
datasets the InChiKeys were compared. 
The SMILES strings for all datasets were inputted into the RDKit (v. 2020.03.6; 
www.rdkit.org) Descriptor Node, accessed through KNIME software (v. 4.3.1; 
www.knime.com), in order to obtain the physico-chemical properties for all chemicals. 
Properties included molecular weight, number of hydrogen bond donors / acceptors, 
predicted logarithm of the octanol:water partition coefficient (SlogP) and the topological 
polar surface area (TPSA); the number of Lipinksi rule violations were calculated from this 
information. Whilst it is possible to generate thousands of physico-chemical properties, here 
only a few readily calculable properties were selected, representing those most often used 
to broadly characterise chemicals in terms of size, polarity and partitioning behaviour. These 
simple properties were also used to determine Lipinksi rule violations, frequently used to 
indicate potential oral absorption – a common route of administration for these models. 
The minimum, maximum, mean and median values and interquartile ranges of these 
properties were calculated using Minitab version 19.2 for all datasets. Histograms were also 
generated using Microsoft Excel to enable a visual comparison of the property ranges 
between the different datasets. The results of the statistical analysis are available as 






Figure 2 summarises the number of papers considered at each stage of the review process 
and the final number of models extracted in the PBK model spreadsheet. Of the 6,771 of 
papers initially identified, 3,120 remained after abstract screening and data were extracted 
from 1,649 of these.  
[FIGURE 2 NEAR HERE]  
 
 
Extraction of data from available PBK models 
A total of 7,541 individual models were identified and extracted. Note that for an individual 
substance multiple models may be available in one paper. For example, if male and female 
subjects were used and doses given intravenously and by oral dosing this would be classed 
as four models, this enables more flexible searching; searches can be conducted, not just by 
chemical names, but also by species or route of administration etc. A total of 1,889 chemical 
names are present in the PBK model dataset, some represent biological entities (such as 
monoclonal antibodies) or are not associated with a specific structure, resulting in 1,187 
unique InChiKeys, i.e. unique chemicals with identifiable structures. Summary information 
concerning the PBK models extracted is shown in Figures 3 and 4. Figure 3 shows the 
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breakdown of models by species investigated and Figure 4 shows the breakdown by route 
of administration.  
[FIGURE 3 NEAR HERE] 
[FIGURE 4 NEAR HERE] 
 
 
Assessment of the chemical space coverage of the PBK model dataset in relation to other 
chemical datasets 
The results for the comparison of InChiKeys for chemicals in the PBK model dataset to those 
for the six comparative datasets are shown in Table 1.  
Table 1. The number (and percentage) of chemicals with existing PBK models that are 
present in the six comparative datasets investigated. 
Dataset 
Number of chemicals in 
dataset (with unique, 
identifiable structure) 
Number of chemicals in 
dataset also present in 
PBK model dataset 
Percentage of chemicals in 
dataset also present in PBK 
model dataset (%) 
PBK model 1,186 N/A N/A 
Botanical  947 24 2.67 
Pesticide 945 40 4.23 
COSMOS  5,655 123 2.41 
Food  2,674 88 3.37 
DrugBank 6,716 382 5.80 
REACH 75,663 620 0.85 
 
Table 2 shows the results of the statistical analysis of the key physico-chemical properties 
(molecular weight, number of hydrogen bond donors and acceptors, logarithm of the 
octanol:water partition coefficient, topological surface area and number of Lipinksi rule 













*MW = molecular weight; No. HBD = number of hydrogen bond donors; No. HBA = number of 
hydrogen bond acceptors; SlogP = predicted logarithm of the octanol:water partition coefficient; 
TPSA = topological polar surface area; nViolations = number of violations of the Lipinski Rule of Five 
(Lipinski et al 1997). 
bThe extreme values here are for vistarem a magnetic resonance imaging contrast agent with large 
hydrophilic chains 
 
Supplementary Material (ii) shows the results of a similar statistical analysis of the physico-
chemical properties for the six datasets to which the PBK model dataset was compared. 
Figure 5 (A-F) shows the comparison of these key physico-chemical properties across the 
seven datasets. 
 
[FIGURE 5 NEAR HERE] 
  
Assessment of screening and data extraction reliability 
After screening all 6,771 abstracts in duplicate, 3,120 were taken forward to full text 
screening; of these, 1,362 papers were rejected at this stage. In addition, 109 papers could 
not be readily obtained or were not in English, therefore data were extracted from 1,649 
papers, resulting in 7,541 models. The resultant spreadsheet comprises over 150,000 
individual entries as for each model the species, sex, life-stage, route of administration, 
availability of equations, compartments, references and chemical identifiers were captured. 
It is expected that errors will arise when assessing the suitability of papers for inclusion and 
performing extensive manual processing, hence a quality assessment exercise was 
Variablea Mean Minimum Q1 Median Q3 Maximum Range IQR 
MW 325.61 6.94 163.10 292.28 410.67 6496.20b 6489.26 247.57 
No. HBD 1.79 0.00 0.00 1.00 2.00 100.00 100.00 2.00 
No. HBA 4.17 0.00 1.00 3.00 6.00 120.00 120.00 5.00 
SlogP 2.25 -45.03b 0.80 2.08 3.73 11.10 56.13 2.93 
TPSA 73.07 0.00 23.47 56.92 93.00 2536.36 2536.36 69.53 
nViolations 0.37 0.00 0.00 0.00 0.00 4.00 4.00 0.00 
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undertaken. Three aspects of the screening and data extraction processes were reviewed by 
a second investigator: 
(i) 5 % of the papers that had been excluded at the full text screening phase were reviewed. 
(ii) 5 % of PBK model data extracted from the papers (chemical information, species data 
(primary and secondary categories), sex, life-stage, route of administration, reference (DOI 
and PubMed ID if available), compartments investigated, availability of equations and 
simulation software were checked. 
(iii) 5 % of the chemical identifier information from PubChem and COSMOS (chemical name, 
CAS registry number, molecular weight, canonical SMILES, isomeric SMILES, InChiKey, 
COSMOS ID) was obtained again from these sources and compared to the values in the 
spreadsheet. 
The greatest source of “error” was determined to be the exclusion of papers that were 
considered as potentially relevant by a second investigator i.e. 6% of excluded papers. In 
terms of the systematic review this is not considered a highly significant problem. PBK 
models are continually being published, hence there can never be a finalised set of models. 
It is the intention to make this resource available in its current form, as a tool to assist 
researchers in finding relevant PBK models, and to update the resource in future capturing 
models previously not identified or erroneously excluded. 
For PBK model data, manually extracted from the papers, an error was detected in the 
information captured for 3.5 % of substances. This does not equate to 3.5 % of the total 
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information being incorrect as this may indicate an error in only one (or possibly more) of 
the 13 columns that relate to the PBK model information.  
An error was detected in the data for 2.4% of the chemicals in relation to the identifier 
information. As above, this does not equate to 2.4% of the total information being incorrect, 
but that for 2.4% of chemicals an error was detected in one (or more) of the 7 columns 
associated with chemical identifier information. 
The authors welcome any feedback from users regarding errors, omissions of existing 
models or updates for new models (note that models require a minimum level of 
information and novelty to be included) please e-mail the corresponding author. 
Discussion 
In this systematic review, information concerning over 7,500 PBK models were extracted 
from 1,649 papers. The models encompassed 18 species (including rat, human, mouse, cow, 
guinea-pig) at various life-stages (e.g juvenile, adult, pregnant, health-compromised) across 
21 administration routes (e.g. oral, inhalation, in utero). The information has been distilled 
into a Microsoft Excel spreadsheet that was constructed using controlled vocabulary to 
enable users to search using different criteria (e.g. to select models by species or routes of 
administration etc). It is anticipated that researchers or regulatory scientists can use this 
information to assist building or evaluation of new models, or as a resource from which to 
extract relevant pharmacokinetic or toxicokinetic data.  
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Although this is the largest collation of PBK models that the authors are aware of, it is not a 
complete list. As identified in the quality assessment exercise, some of the historic models 
were omitted, also it would not be possible to generate a finite list of all models as this is 
such a dynamic area of research. The publication of new models has shown a rapidly 
increasing trajectory in recent years,26 the current dataset serves as a basis for continuing 
curation of existing models which will provide an increasingly rich source of information for 
modellers in future.  
Chemicals can be used for a variety of purposes and it is often not feasible to allocate a 
chemical to unique group (e.g. there is a significant cross-over between chemicals used as 
food additives and as cosmetic ingredients, hence the same chemicals may appear in more 
than one of the different datasets). It is therefore difficult to determine for which chemical 
“types” there are most PBK models, however there are some trends discernible from the 
analysis undertaken. Unsurprisingly, given that PBK modelling evolved in drug development, 
the greatest proportion of models correspond to chemicals in the DrugBank dataset. 
Pesticides are generally well studied and data-rich, therefore the second most common type 
of chemical with PBK models are the pesticides. For food additives and cosmetic ingredients, 
where there are often chemicals in common, similar proportions of chemicals have PBK 
models. Due to the size and generality of the REACH dataset it would be anticipated that 
relatively few chemicals would have existing PBK models. The results confirm the paucity of 
PBK models available in relation to different areas of chemical space and underline the 
importance of using existing PBK models to help fill data gaps. 
Figure 5.A shows the distribution of molecular weight across the seven datasets. As 
expected, the majority of chemicals fall within the range 100-600 Da but there are notable 
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differences between the datasets. There are a relatively high number of chemicals in the 
PBK dataset with low molecular weight, these will include the volatile chemicals for which 
respiratory uptake has been extensively studied. Food additives and cosmetic ingredients 
(which have chemicals in common) show a relatively high proportion of low molecular 
weight chemicals. Chemicals that are designed to be biologically active, such as drugs and 
pesticides, tend to be developed in accordance with guidelines relating to preferred 
physico-chemical properties. For example, the Lipinski Rule of Five stipulates that poor oral 
absorption of drugs is associated with those chemicals having molecular weight > 500 Da; 
log P > 5; >10 hydrogen bond acceptors or; > 5 hydrogen bond donors.27 Other research has 
also suggested that TPSA >140A2 is also unfavourable for oral absorption, consequently 
certain chemical types are designed to fall within narrower property ranges and such trends 
are evident in the property ranges here. A correlation between molecular weight and log P 
is often observed amongst groups of chemicals (although there are many exceptions to 
this), here a similar pattern to the range of values is generally observed for log P and 
molecular weight. Pesticide and botanical datasets have a greater percentage of chemicals 
in the log P ranges 3-4 (43% and 47% respectively), whereas the PBK dataset only has 28% of 
chemicals in this range. Pesticide and botanical datasets comprise fewer molecules capable 
of carrying a charge (associated with increased hydrophilicity) hence on average have higher 
log P values. This is significant as partitioning behaviour (often estimated using log P) is a 
key element in building PBK models. Whilst the extreme values for log P, calculated by the 
software used here, may be unrealistic (and therefore unsuitable for model building), when 
used for comparison they are still useful for demonstrating the trends in the data. The range 
in values for all of the physico-chemical properties of pesticides, is narrower than for the 
other chemical types, indicating the more restrictive chemical properties required for these 
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chemicals. Botanicals generally show a wider range of values for each of the physico-
chemical properties (in particular more chemicals show properties at the upper extremes of 
the ranges). A significant number of compounds within this set are large and complex. 
Whilst in other datasets, molecules tend to be designed for a specific purpose (and those 
outwith given property ranges are filtered out) the same exclusions would not be applicable 
to this dataset.  
 
Conclusion 
Understanding the kinetic behaviour of a chemical within the body, particularly its 
concentration-time profile at a target site, is essential to accurately determine its potential 
effect. For the majority of chemicals there is a lack of data concerning toxicity and kinetics, 
however generating such information de novo would require excessive use of animals and is 
legally, ethically and financially constrained. Hence there is a need to leverage existing 
knowledge in order to obtain as much information as possible to assist decision making. 
Read-across is the most common method used by which information from data-rich 
chemicals is used to predict information for data-poor chemicals. Herein is presented a 
comprehensive collation of existing PBK models that can be searched using multiple criteria. 
The physico-chemical space of PBK models has been mapped against that of other chemical 
types ie. food additives, cosmetic ingredients, drugs, REACH chemicals, botanicals and 
pesticides. Organising the current state of knowledge of existing PBK models provides a 
valuable resource for those working in the area to identify models for chemicals of interest, 
or analogues, that can be used to assist the development or evaluation of new PBK models. 
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The concept of using existing PBK model information in a read-across approach to develop a 
new PBK model for an analogous chemical has been demonstrated successfully in recent 
publications.18,22 Such an approach is recommended in the recent OECD guidance on PBK 
modelling which focuses on the use of alternative methods in PBK model development.10 
The PBK model dataset described herein enables researchers to readily gain insight into 
available PBK models across multiple species, life-stages and routes of administration, such 
that the structure and parameterisation of PBK models for different chemicals is more 
accessible. This ensures maximum use of existing knowledge on PBK modelling and reduces 
the time and cost associated with developing new PBK models.  
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Continuing effort is required to curate existing PBK models. The ability to extract relevant 
data from models and reproduce those published in literature would be facilitated by 
researchers embracing the use of systematic methods to record PBK models. Consistent 
formats for publishing PBK models have been proposed previously,28,29 with the template 
proposed in the recent OECD guidance10 drawing on previous recommendations, most 
significantly the reporting format proposed by Tan and co-workers30. Use of consistent 
reporting formats is strongly encouraged as this assists other researchers in re-using or re-
purposing existing models.  
Future effort is required to curate available models, identify appropriate similarity metrics 
to assist in the identification of PBK models for analogues to chemicals of interest and, 
ideally, to make such resources widely available, for example by incorporation into free 
webtools. Such endeavours will help to leverage the wealth of information available in 





Supporting information to accompany this manuscript includes: 
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Supplementary material (i) a Microsoft Excel file incorporating the spreadsheet used to 
capture model information for over 7,500 models, an explanation of the controlled 
vocabulary employed, and the physico-chemical properties of the chemicals for which a PBK 
model has been identified. 
Supplementary material (ii) full results of the statistical analysis of the chemical space of the 
datasets investigated. 
Supplementary material (iii) PRISMA compliance checklist for systematic reviews 
The Endnote library of papers from which the model data were extracted is available on 
request; references / DOIs are available in the Microsoft Excel sheet in Supplementary 
Material (i).  
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